Clinical Trial Update: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update investigating a reduced treatment strategy using a SOF/Glecepravir-pibrentasvir regimen for very early liver disease due to hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Glecepravir-pibrentasvir (glecepravir-pibrentasvir)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Kirby Institute | Conditions: Hepatitis C | Phase 4 | Status: UNKNOWN